Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid.
Bittner T, Zetterberg H, Teunissen CE, Ostlund RE Jr, Militello M, Andreasson U, Hubeek I, Gibson D, Chu DC, Eichenlaub U, Heiss P, Kobold U, Leinenbach A, Madin K, Manuilova E, Rabe C, Blennow K. Bittner T, et al. Among authors: rabe c. Alzheimers Dement. 2016 May;12(5):517-26. doi: 10.1016/j.jalz.2015.09.009. Epub 2015 Nov 10. Alzheimers Dement. 2016. PMID: 26555316 Free article.
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.
Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke V, Corradini V, Eichenlaub U, Batrla R, Buck K, Zink K, Rabe C, Blennow K, Shaw LM; Swedish BioFINDER study group; Alzheimer's Disease Neuroimaging Initiative. Hansson O, et al. Among authors: rabe c. Alzheimers Dement. 2018 Nov;14(11):1470-1481. doi: 10.1016/j.jalz.2018.01.010. Epub 2018 Mar 1. Alzheimers Dement. 2018. PMID: 29499171 Free PMC article.
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, Quartino A, Clayton D, Mortensen D, Bittner T, Ho C, Rabe C, Schauer SP, Wildsmith KR, Fuji RN, Suliman S, Reiman EM, Chen K, Paul R. Salloway S, et al. Among authors: rabe c. Alzheimers Res Ther. 2018 Sep 19;10(1):96. doi: 10.1186/s13195-018-0424-5. Alzheimers Res Ther. 2018. PMID: 30231896 Free PMC article. Clinical Trial.
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, Cassetta E, Woodward M, Boada M, van Dyck CH, Grimmer T, Selkoe DJ, Schneider A, Blondeau K, Hu N, Quartino A, Clayton D, Dolton M, Dang Y, Ostaszewski B, Sanabria-Bohórquez SM, Rabbia M, Toth B, Eichenlaub U, Smith J, Honigberg LA, Doody RS. Ostrowitzki S, et al. Among authors: rabe c. JAMA Neurol. 2022 Nov 1;79(11):1113-1121. doi: 10.1001/jamaneurol.2022.2909. JAMA Neurol. 2022. PMID: 36121669 Free PMC article. Clinical Trial.
Clinical performance and robustness evaluation of plasma amyloid-β42/40 prescreening.
Rabe C, Bittner T, Jethwa A, Suridjan I, Manuilova E, Friesenhahn M, Stomrud E, Zetterberg H, Blennow K, Hansson O; Alzheimer's Disease Neuroimaging Initiative† and the Swedish BioFINDER study. Rabe C, et al. Alzheimers Dement. 2023 Apr;19(4):1393-1402. doi: 10.1002/alz.12801. Epub 2022 Sep 23. Alzheimers Dement. 2023. PMID: 36150024
Identifying clinically useful biomarkers in neurodegenerative disease through a collaborative approach: the NeuroToolKit.
Johnson SC, Suárez-Calvet M, Suridjan I, Minguillón C, Gispert JD, Jonaitis E, Michna A, Carboni M, Bittner T, Rabe C, Kollmorgen G, Zetterberg H, Blennow K. Johnson SC, et al. Among authors: rabe c. Alzheimers Res Ther. 2023 Jan 28;15(1):25. doi: 10.1186/s13195-023-01168-y. Alzheimers Res Ther. 2023. PMID: 36709293 Free PMC article.
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force.
Angioni D, Hansson O, Bateman RJ, Rabe C, Toloue M, Braunstein JB, Agus S, Sims JR, Bittner T, Carrillo MC, Fillit H, Masters CL, Salloway S, Aisen P, Weiner M, Vellas B, Gauthier S. Angioni D, et al. Among authors: rabe c. J Prev Alzheimers Dis. 2023;10(3):418-425. doi: 10.14283/jpad.2023.68. J Prev Alzheimers Dis. 2023. PMID: 37357282
Deep Learning to Predict Geographic Atrophy Area and Growth Rate from Multimodal Imaging.
Anegondi N, Gao SS, Steffen V, Spaide RF, Sadda SR, Holz FG, Rabe C, Honigberg L, Newton EM, Cluceru J, Kawczynski MG, Bengtsson T, Ferrara D, Yang Q. Anegondi N, et al. Among authors: rabe c. Ophthalmol Retina. 2023 Mar;7(3):243-252. doi: 10.1016/j.oret.2022.08.018. Epub 2022 Aug 28. Ophthalmol Retina. 2023. PMID: 36038116 Free article.
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.
Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, Quartino A, Honigberg LA, Fuji RN, Clayton D, Mortensen D, Ho C, Paul R. Cummings JL, et al. Among authors: rabe c. Neurology. 2018 May 22;90(21):e1889-e1897. doi: 10.1212/WNL.0000000000005550. Epub 2018 Apr 25. Neurology. 2018. PMID: 29695589 Free PMC article. Clinical Trial.
136 results